New Research: A Recognizable Weight Loss & Diabetes Drug May Harm Vision
Some eye doctors were noticing a trend among patients that researchers in Europe now believe has been well demonstrated with data.
America’s love-hate relationship with the new weight-loss drugs
Nearly half of US adults admit they’d take one of the newer, injectable weight loss drugs, but that number falls significantly when they learn that the weight might come back when the meds are stopped.
Lilly asks to join lawsuit over compounded versions of its weight-loss drugs
Eli Lilly has asked to join in opposing a lawsuit brought by compounding pharmacies against the U.S. Food and Drug Administration over the agency's decision that Lilly's blockbuster weight-loss and diabetes drugs are no longer in short supply.
Lilly and Novo Went Head-to-Head Over Weight-Loss Drugs in 2024. There’s a Clear Winner.
It hasn’t been a smooth year for the two pharma giants, but events in the fourth quarter widened the gap between them.
Weight-loss drugs are popular among national stories of 2024
What a year! What do you think was the most important news in the United States in 2024? This list probably doesn’t reflect that. Rather, it shows what you, the readers, were looking at on EastIdahoNews.
FDA approves weight-loss drug Zepbound to treat sleep apnea
Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration for treating moderate to severe obstructive sleep apnea.
Pharma giant seeks to join lawsuit against FDA over weight loss drugs
Eli Lilly is seeking to end a lawsuit filed by a pharmacy trade group against the Food and Drug Administration (FDA) by joining as a defendant, stating it wants to end the “entitlement” some pharmacies have practiced in mass-marketing copies of its highly popular GLP-1 medications.
Lilly seeking to join lawsuit over compounded GLP-1 drugs
Eli Lilly (NYSE:LLY) is reportedly seeking to oppose a lawsuit filed by compounding pharmacies over the FDA's determination that weight-loss and diabetes drugs such as Lilly's (NYSE:LLY) tirzepatide are no longer in short supply.
Ozempic and Similar Drugs May Offer Health Benefits Beyond Weight Loss, Including Reduced Alcohol Cravings
Ozempic, Wegovy and Mounjaro, all GLP-1 anti-obesity medications, may offer health benefits beyond weight loss. Studies show ...
PBS1d
As weight loss drug demand soars, physician outlines effectiveness and potential downsides
For weight loss drugs like Ozempic and Wegovy, 2024 was a big year. More patients are relying on them to manage their weight, treat diabetes, or prevent heart attacks and strokes. And while they are ...
Elon Musk admits to taking controversial weight loss drug previously opposed by RFK Jr.
Billionaire entrepreneur and top adviser to President-elect Donald Trump, Elon Musk, touted that he has reaped the benefits of Ozempic after fellow top Trump adviser, Robert F. Kennedy Jr., suggested ...
2024 was the year of weight loss for Floridians. Wondering why?
For Floridians, 2024 was a year of weight loss and emerging revelations about anti-obesity medications.
IBX will no longer cover drugs like Ozempic when they are prescribed solely for weight loss
GLP-1 receptor agonists, which can cost around $1,300 a month, have caused an increase in premiums that “affect all members, ...
Some patients want to take a holiday pause on diabetes or weight-loss drugs. Here’s what doctors say they need to know
Around the holidays – when many people are baking cookies for Santa, enjoying cocktail parties or having festive family feasts – some adults who use popular medications for diabetes or weight loss ...